Persistent paralysis in critically ill patients after long-term administration of vecuronium.

BACKGROUND The muscle relaxant vecuronium is sometimes administered to facilitate mechanical ventilation. Neuromuscular paralysis lasting up to seven days may occur after the termination of long-term administration (i.e., more than two days) of vecuronium in critically ill patients. We investigated the role of clinical factors and plasma concentrations of vecuronium and its metabolite in causing this prolonged neuromuscular blockade. METHODS We studied 16 critically ill adult patients (8 women and 8 men) who had received vecuronium to facilitate mechanical ventilation for at least two consecutive days. Clinical factors and plasma concentrations of vecuronium and 3-desacetylvecuronium, the active metabolite of vecuronium, were compared in patients with and without prolonged neuromuscular blockade. In addition, we performed detailed pharmacokinetic studies in the patients without prolonged neuromuscular blockade. RESULTS Seven of the 16 patients had prolonged neuromuscular blockade, lasting from six hours to more than seven days, after the termination of vecuronium therapy. These seven patients, six of whom were women, had higher plasma magnesium concentrations and lower arterial blood pH values than the nine patients without prolonged neuromuscular blockade. They also had higher plasma concentrations of 3-desacetylvecuronium and a higher frequency of renal failure (seven of seven patients vs. four of nine patients, P less than 0.03). In the patients without prolonged neuromuscular blockade, the mean (+/- SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5 +/- 1.0 ml per kilogram of body weight per minute, 299 +/- 154 minutes, and 1.1 +/- 0.6 liters per kilogram, respectively. CONCLUSIONS Prolonged neuromuscular blockade after the termination of long-term treatment with vecuronium is associated with metabolic acidosis, elevated plasma magnesium concentrations, female sex, and probably more important, the presence of renal failure and high plasma concentrations of 3-desacetylvecuronium.

[1]  E. O'sullivan,et al.  Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. , 1991, British Journal of Anaesthesia.

[2]  R. Miller,et al.  Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. , 1991, Anesthesiology.

[3]  P. Duvaldestin,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium (ORG NC 45) in Patients with Cirrhosis , 1985, Anesthesiology.

[4]  W. Sibbald,et al.  Peripheral nerve function in sepsis and multiple organ failure. , 1991, Chest.

[5]  G. Koren,et al.  FENTANYL ANESTHESIA FOR CARDIAC SURGERY IN CHILDRENa) FENTANYL-OXYGEN VS FENTANYL-N2O; b) RELATIONSHIP BETWEEN DRUG CONCENTRATIONS AND PHARMACODYNAMICS , 1984 .

[6]  Ronald D. Miller,et al.  Continuous Infusion of Vecuronium: The Effect of Anesthetic Agents , 1987, Anesthesiology.

[7]  S. Carpenter,et al.  Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment , 1991, Muscle & nerve.

[8]  M. Houwertjes,et al.  Disposition of vecuronium bromide in the cat. , 1985, British journal of anaesthesia.

[9]  R. Mirakhur,et al.  Vecuronium infusions for prolonged muscle relaxation in the intensive care unit , 1989, Critical care medicine.

[10]  Ronald D. Miller,et al.  The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal Failure , 1988, Anesthesiology.

[11]  R. Miller,et al.  Renal and Biliary Elimination of Vecuronium (ORG NC 45) and Pancuronium in Rats , 1982, Anesthesia and analgesia.

[12]  Y. Ohta,et al.  The Influence of Respiratory‐induced Acid‐base Changes on the Action of Non‐depolarizing Muscle Relaxants in Rats , 1988, Anesthesiology.

[13]  R. Miller,et al.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. , 1981, British Journal of Anaesthesia.

[14]  R. Miller,et al.  Quantitation of pancuronium, 3-desacetylpancuronium, vecuronium, 3-desacetylvecuronium, pipecuronium and 3-desacetylpipecuronium in biological fluids by capillary gas chromatography using nitrogen-sensitive detection. , 1988, Journal of chromatography.

[15]  R. Miller,et al.  Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. , 1990, Anesthesiology.

[16]  D. Green,et al.  Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. , 1990, The Journal of clinical investigation.

[17]  John C. Cannon,et al.  Vecuronium in Alcoholic Liver Disease: A Pharmacokinetic and Pharmacodynamic Analysis , 1988, Anesthesiology.

[18]  M. Houwertjes,et al.  Effects of hepatic uptake of vecuronium bromide and its putative metabolites on their neuromuscular blocking actions in the cat. , 1985, British journal of anaesthesia.

[19]  J. Hunter,et al.  Vecuronium infusions in patients with renal failure in an ITU , 1987, Anaesthesia.

[20]  A. Kopman,et al.  Milliamperage requirements for supramaximal stimulation of the ulnar nerve with surface electrodes. , 1984, Anesthesiology.

[21]  D. Coursin,et al.  Increased requirements for continuously infused vecuronium in critically ill patients. , 1989, Anesthesia and analgesia.

[22]  P. Waser,et al.  Distribution and kinetics of 14C-vecuronium in rats and mice. , 1987, British journal of anaesthesia.

[23]  C. Meistelman,et al.  Pharmacology of vecuronium in patients with end-stage renal failure. , 1986, European Journal of Anaesthesiology.

[24]  I. G. Marshall,et al.  Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat. , 1983, British journal of anaesthesia.

[25]  J. Viby-Mogensen,et al.  Clinical assessment of neuromuscular transmission. , 1982, British Journal of Anaesthesia.

[26]  J. Crul,et al.  Effects of Changes in Acid‐Base Balance on Neuromuscular Blockade Produced by ORG‐NC 45 , 1980, Acta anaesthesiologica Scandinavica.